U.S. Markets closed

Earnings Estimates Moving Higher for Vical (VICL): Time to Buy?

Zacks Equity Research

Vical Inc. (VICL), a biopharmaceutical company, could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on VICL’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Vical could be a solid choice for investors.

Current Quarter Estimates for VICL

In the past 30 days, 1 estimate has gone higher for Vical while no estimate moved lower in the same time period. The trend has been pretty favorable too, with loss estimates narrowing from a loss of 6 cents per share 30 days ago, to a loss of 5 cents per share today, a move of 16.7%.

Current Year Estimates for VICL

Meanwhile, Vical’s current year figures are also looking quite promising, with 1 estimate moving higher in the past month, compared to no estimates moving lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 22 cents per share 30 days ago to a loss of 19 cents per share today, an increase of 13.6%.

Bottom Line

The stock has also started to move higher lately, adding 5.2% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

VICAL INC (VICL): Free Stock Analysis Report

Zacks Investment Research